ponatinib versus ascimininib in the third-line treatment of cml
Published 1 year ago • 452 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
1:43
dosing strategy of ponatinib in cp-cml: insights from the optic trial
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
1:37
optic: ponatinib in chronic-phase cml
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
1:13:43
connected care: remote monitoring of non-invasive ventilation in hospital i philips
-
27:06
monclonal antibodies, antibody fragments and peptides
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
1:27
novel agents or imatinib for cml in the frontline setting?
-
8:57
outcomes of sct in t-all and t-lbl
-
3:40
outcomes of all stratified by socioeconomic factors
-
2:12
using a novel machine learning model to analyze and predict the outcomes of patients with ndmm
-
4:19
optic: ponatinib in resistant chronic-phase cml
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
3:18
granulocytes & t-cells as biomarkers for relapse in cml following discontinuation of tkis
-
6:02
predicting treatment outcomes in patients with r/r chl with ctdna and pet
-
1:09
sequencing of therapies to improve outcomes of cll patients
-
1:44
the importance of patient-reported outcomes in clinical trials & clinical practice